VISTA PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.39 INR | +3.72% |
|
+2.61% | -8.73% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 983.6 | 608 | 160.9 | 403.6 | 339.2 | 311.9 |
| Enterprise Value (EV) 1 | 1,076 | 711 | 313.4 | 552 | 464 | 409.5 |
| P/E ratio | 50.3 x | 67.2 x | -4.34 x | -16.6 x | -40.8 x | -5.44 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.4 x | 1.96 x | 0.71 x | 31.9 x | 86 x | 31.1 x |
| EV / Revenue | 3.72 x | 2.29 x | 1.38 x | 43.6 x | 118 x | 40.8 x |
| EV / EBITDA | 13.9 x | 38.3 x | -7.01 x | -31.9 x | -38.3 x | -10.5 x |
| EV / FCF | -6.67 x | -12.3 x | -10.4 x | 69.9 x | -46.9 x | -16 x |
| FCF Yield | -15% | -8.11% | -9.66% | 1.43% | -2.13% | -6.23% |
| Price to Book | 3.36 x | 1.71 x | 0.54 x | 1.01 x | 0.96 x | 0.86 x |
| Nbr of stocks (in thousands) | 26,800 | 30,175 | 30,365 | 44,651 | 36,794 | 37,309 |
| Reference price 2 | 36.70 | 20.15 | 5.300 | 9.040 | 9.220 | 8.360 |
| Announcement Date | 7/22/18 | 8/26/19 | 12/7/20 | 9/1/21 | 9/7/22 | 9/7/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 289.2 | 310.7 | 227.6 | 12.66 | 3.945 | 10.04 |
| EBITDA 1 | 77.62 | 18.58 | -44.72 | -17.3 | -12.11 | -38.84 |
| EBIT 1 | 64.26 | 4.94 | -58.19 | -24.57 | -18.27 | -45.01 |
| Operating Margin | 22.22% | 1.59% | -25.57% | -194.04% | -463.07% | -448.47% |
| Earnings before Tax (EBT) 1 | 28.27 | 11.47 | -39.36 | -36.88 | -25.61 | -58.76 |
| Net income 1 | 21.86 | 9.394 | -36.77 | -18.85 | -8.319 | -56.62 |
| Net margin | 7.56% | 3.02% | -16.16% | -148.86% | -210.87% | -564.11% |
| EPS 2 | 0.7300 | 0.3000 | -1.220 | -0.5441 | -0.2261 | -1.537 |
| Free Cash Flow 1 | -161.4 | -57.64 | -30.26 | 7.895 | -9.902 | -25.52 |
| FCF margin | -55.81% | -18.55% | -13.29% | 62.34% | -250.99% | -254.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 7/22/18 | 8/26/19 | 12/7/20 | 9/1/21 | 9/7/22 | 9/7/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 92.8 | 103 | 152 | 148 | 125 | 97.6 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.195 x | 5.542 x | -3.408 x | -8.578 x | -10.31 x | -2.512 x |
| Free Cash Flow 1 | -161 | -57.6 | -30.3 | 7.9 | -9.9 | -25.5 |
| ROE (net income / shareholders' equity) | 9.02% | 2.78% | -11.2% | -6.03% | -2.44% | -15.7% |
| ROA (Net income/ Total Assets) | 8.49% | 0.58% | -7% | -3.01% | -2.15% | -5.04% |
| Assets 1 | 257.6 | 1,609 | 525.2 | 625.9 | 387.8 | 1,123 |
| Book Value Per Share 2 | 10.90 | 11.80 | 9.760 | 8.930 | 9.640 | 9.770 |
| Cash Flow per Share 2 | 0.6100 | 0.2900 | 0.0700 | 0.0400 | 0.0200 | 0.0500 |
| Capex 1 | 86.2 | 33.2 | 2.44 | 2.99 | 0.14 | 12.7 |
| Capex / Sales | 29.82% | 10.67% | 1.07% | 23.61% | 3.62% | 126.56% |
| Announcement Date | 7/22/18 | 8/26/19 | 12/7/20 | 9/1/21 | 9/7/22 | 9/7/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -8.73% | 10.27M | |
| +17.43% | 42.25B | |
| +15.37% | 21.27B | |
| +19.51% | 15.23B | |
| +19.84% | 14.36B | |
| +51.59% | 12.74B | |
| -0.05% | 6.79B | |
| -12.40% | 6.61B | |
| -8.87% | 5.73B | |
| +14.28% | 5.66B |
- Stock Market
- Equities
- VISTAPH6 Stock
- Financials Vista Pharmaceuticals Limited
